CNST Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Stats
Šios dienos apimtis	1.27M
Vidutinė apimtis	1.57M
Rinkos kapitalizacija	0.00
EPS	$0 ( 2021-08-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.734 (2.16%)

Insider Trading

Date	Person	Action	Amount	type
2021-07-15	Hoerter Steven L.	Sell	26 342	Stock Option (right to buy)
2021-07-15	Reeve Emma	Sell	60 000	Stock Option (Right to Buy)
2021-07-15	Reeve Emma	Sell	37 527	Stock Option (right to buy)
2021-07-15	Reeve Emma	Sell	73 428	Stock Option (right to buy)
2021-07-15	Reeve Emma	Sell	11 777	Stock Option (right to buy)

INSIDER POWER
0.00
Last 99 transactions
Buy: 291 157 \| Sell: 1 004 317

Tūris Koreliacija

Ilgas: 0.27 (neutral)

Trumpas: 0.71 (moderate)

Signal:(80.978) Neutral

Constellation Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
TLMD	0.947
MDWT	0.94
RMRM	0.926
ATOM	0.923
SVOK	0.923
MDXG	0.92
NNOX	0.918
WWD	0.918
LIXT	0.916
MEIP	0.915

10 Labiausiai neigiamai susiję koreliacijos
BOCH	-0.944
SMSI	-0.929
APTX	-0.92
TWKS	-0.917
UPLD	-0.913
MMAC	-0.905
NETE	-0.903
TTEC	-0.903
EYE	-0.901
INGN	-0.896

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Constellation Koreliacija - Valiuta/Žaliavos

0.09
( neutral )

0.46
( neutral )

0.02
( neutral )

0.43
( neutral )

0.70
( moderate )

0.14
( neutral )

Constellation Finansinės ataskaitos

Annual	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-4.49

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-4.49

FY	2019
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-3.04

FY	2018
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-5.00

Financial Reports:

No articles found.

Constellation

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.